"Muu" projekt 3.2.1001.11- 0017
3.2.1001.11- 0017 "Parkinsoni tõve epidemioloogia ja molekulaarne patogenees (1.01.2012−30.06.2015)", Pille Taba, Eesti Liigutushäirete Selts.
3.2.1001.11- 0017
3.2.1001.11- 0017
Parkinsoni tõve epidemioloogia ja molekulaarne patogenees
Epidemiology and molecular pathogenesis of Parkinson's Disease
Teadus- ja arendusprojekt
ETIS klassifikaatorAlamvaldkondCERCS klassifikaatorFrascati Manual’i klassifikaatorProtsent
3. Terviseuuringud3.7. Kliiniline meditsiinB640 Neuroloogia, neuropsühholoogia, neurofüsioloogia 3.2. Kliiniline meditsiin (anestesioloogia, pediaatria, sünnitusabi ja günekoloogia, sisehaigused, kirurgia, stomatoloogia, neuroloogia, psühhiaatria, radioloogia, terapeutika, otorinolarüngoloogia, oftalmoloogia)100,0
Eesti Liigutushäirete Seltskoordinaator01.01.2012−30.06.2015
SA Archimedes
01.01.2012−30.06.2015376 200,00 EUR
376 200,00 EUR
EU European Regional Development Fund: TerVe programm

The current project aims to study the epidemiological trends and molecular pathogenesis of Parkinson’s disease (PD): 1) A cross-sectional epidemiological study, including clinical and pharmaco-epidemiological assessment of the patient cohort, to characterize the PD condition in the Estonian population. 2) Transcriptomic profiling of PD patient skin tissue samples using next generation RNA sequencing technology, to provide information on the molecular mechanisms of PD changes which are reflected in skin that could assist in finding potential biomarkers PD. 3)Gene expression and protein levels of markers of melanocortic pathway from skin bioptates of PD patients versus controls. 4) Chracterization of the profile of novel CDNF/MANF neurotrophic growth factor family in the PD patients blood serum, skin and blood samples. These factors have been shown to have potential in disease modifying therapy of PD models in animals, but studies on human samples have never been performed. These results may provide additional understanding the pathogenic mechanisms of PD in humans and provide evidence for biomarkers of the disease.